This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Breast cancer; lung cancer	PDZ binding kinase (PBK; TOPK)	Mouse studies suggest a selective TOPK inhibitor could be used to treat breast and lung cancer. In over 1,000 patients with breast or lung cancer, increased TOPK expression correlated with a poor prognosis. In a mouse model of TOPK-expressing cancer, a TOPK-selective, liposome-formulated thieno[2,3-c]quinolone derivative called OTS964 caused complete regression of pre-established tumors within 15 days in 6 of 6 animals and only resulted in temporary leukocytopenia and no body weight loss. Ongoing work includes GMP manufacturing of OTS964 by OncoTherapy Science Inc. and designing a Phase I trial to test the compound in patients with acute myeloid leukemia. SciBX 7(44); doi:10.1038/scibx.2014.1286 Published online Nov. 13, 2014	Patent application filed by OncoTherapy Science; OTS964 available under materials transfer agreement	Matsuo, Y. <i>et al. Sci. Transl. Med.</i>; published online Oct. 22, 2014; doi:10.1126/scitranslmed.3010277 Contact: Yusuke Nakamura, The University of Chicago, Chicago, Ill. e-mail: ynakamura@bsd.uchicago.edu